A Comparison of 141W94 and Indinavir in HIV-Infected Patients
- Conditions
- HIV Infections
- Registration Number
- NCT00002202
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
The purpose of this study is to see if 141W94 is as safe and effective as indinavir when used with nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. This study also examines what effect other drugs have on how the body handles 141W94.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 460
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (24)
East Bay AIDS Ctr
🇺🇸Berkeley, California, United States
AIDS Healthcare Foundation
🇺🇸Los Angeles, California, United States
Saint Francis Mem Hosp
🇺🇸San Francisco, California, United States
ViRx Inc
🇺🇸San Francisco, California, United States
Univ of Colorado Health Sciences Ctr
🇺🇸Denver, Colorado, United States
Whitman Walker Clinic Inc
🇺🇸Washington, District of Columbia, United States
CRI of South Florida
🇺🇸Coral Gables, Florida, United States
Community Research Initiative of Central Florida
🇺🇸Maitland, Florida, United States
Univ of Miami Dept of Medicine
🇺🇸Miami, Florida, United States
Northwestern Univ Med School
🇺🇸Chicago, Illinois, United States
Scroll for more (14 remaining)East Bay AIDS Ctr🇺🇸Berkeley, California, United States